

PUBLISHED BY THE U.S. GOVERNMENT PRINTING OFFICE

TEC - CENTER 1300 2900

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

$$(f_{\text{sc}} \text{ is } m_0 D) \wedge (f_{\text{sc}} \text{ is } m_0 \text{ sc } D)$$

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	09/004,352
Filing Date	July 13, 2004
First Named Inventor	BORDERS et al.
Group Art Unit	1653
Examiner Name	
Attorney Docket Number	ENB-007-0418

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	Date Considered	
-----------------------	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPI P-100. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number

See attached kinds of U.S. Patent Documents

Later entries are identified by the two-letter code (WIPO Standard S1.3)

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. If it possible


Applicant(s) to place a check mark here if English language translation was attached.

Please type a plus sign (+) inside this box ☐

RECEIVED

MAR 13 2002

PTO/SB/08A/008-000



TECH-CENTER 1000-2800
Complete if known

Substitute for Form 1449A PTO			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary.)</i>		Application Number	09/043352
		Filing Date	July 13, 2001
		First Named Inventor	BORDERS et al
		Group Art Unit	1653
		Examiner Name	
Sheet	2	of	2
		Attorney Docket Number	INBI-007-0418


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	1
DE		NAGANAWA et al. A Novel Fatty Acid From Laspartomycin. The Journal of Antibiotics, Vol. 23, No. 8, pp. 423-424, August 1970	

Examiner Signature	<i>[Signature]</i>	Date Considered	11/6/01
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number
 2 Applicant is to place a check mark here if English language translation attached

Please type a plus sign (+) inside this box → ☐



RECEIVED

MAY 01 2002

P100813 08X 008000

Substitute for form 1449A P10		Complete TECH CENTER 1600 2900	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	09/004,352
		Filing Date	July 13, 2001
		First Named Inventor	BORDERS et al
		Group Art Unit	1653
		Examiner Name	
Sheet	1	of	2
		Attorney Docket Number	INBI-007 041'S

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
	P6	4,524,135		Abbott et al	06-18-1985
	P7	4,977,083		Boeck	12-11-1990
	P8	4,994,270		Boeck et al	02-19-1991
	P9	5,028,590		Fukuda et al	07-02-1991
	P10	5,039,789		Fukuda et al	08-13-1991
	P11	5,912,226		Baker et al	06-15-1999
	P12	6,194,383	B1	Hammann et al	02-27-2001

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number ¹	Kind Code ² (if known)		

Examiner Signature	<i>[Signature]</i>	Date Considered	<i>[Date]</i>
--------------------	--------------------	-----------------	---------------

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

See attached kinds of U.S. Patent Documents.


Enter Office that issued the document, by the two-letter code (WIPO Standard S1.3).

² For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard S1.16, if possible.

Applicant is to place a check mark here if English language translation is attached.

Please type a plus sign (+) inside this box → ☐



RECEIVED

MAY 03 2001

PLO/SB/CSA/058-000

Complete **TECH CENTER 1600-2900**

Substitute for form 1449A PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number		09/904,352	
		Filing Date		July 13, 2001	
		First Named Inventor		BORDERS et al.	
		Group Art Unit		1653	
		Examiner Name			
Sheet	2	of	2	Attorney Docket Number	INBI-007 041 US


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		1
SL	D2	BODANSKY et al. "Structure of the Peptide Antibiotic Amphomycin", Journal of the Amer. Chem. Soc. 95, April 4, 1973, pp. 2352-2357		
SL	D3	DEBONO et al. "Enzymatic and Chemical Modifications of Lipopeptide Antibiotic A21978C: The Synthesis and Evaluation of Daptomycin (LY146032)", The Journal of Antibiotics, Vol. XI, No. 8, Aug. 1988, pp. 1093-1105		
SL	D4	SHAY et al. "Aspartoic Acid Production, Isolation and Characteristics", Antibiotics Annual 1959-1960, pp. 194-198		
SL	D5	NAGANAWA et al. "Aspartomycin, A New Anti-Staphylococcal Peptide", The Journal of Antibiotics, Vol. 21, Jan. 1968, pp. 55-62		
SL	D6	MARTIN et al. "Isolation and Identification of D- α -Pipicollic Acid, α [L]- β -Methylaspartic Acid and α , β -Diaminobutyric Acid from the Polypeptide Antibiotic Aspartoic", Communications to the Editor, April 20, 1960, pp. 2079		

Examiner Signature	<i>[Signature]</i>	Date Considered	<i>[Signature]</i>
--------------------	--------------------	-----------------	--------------------

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number

2 Applicant is to place a check mark here if English language translation attached



INVENTOR DONALD B. BORDERS	INVENTOR'S ADDRESS 66008142402	APPLICATION NO. 09 904,352
INVENTOR'S NAME Donald B. Borders <i>et al</i>		
FILING DATE July 13, 2001		GROUP ART UNIT 1653

SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary.)

U.S. PATENT DOCUMENTS

EXAMINER (Initials)	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE If Appropriate
AA	4,331,594	05 25 82	Hamill <i>et al</i>	260	112.5 R	
AB	4,800,157	01 24 89	Eaton <i>et al</i>	435	71	
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						

RECEIVED

SEP 05 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
AK					
AL					
AM					
AN					
AO					

COPY MADE
ORIGINAL FILED

OTHER PRIOR ART (Including but not limited to references in the

VI	
VII	
VIII	

EXAMINER

DATE CONSIDERED

EXAMINER

I hereby certify that the information disclosed herein is true and correct to the best of my knowledge and belief, and that I am the inventor or one of the inventors of the invention disclosed herein.